General Forum, page-1028

I'm jealous ... my average is closer to .50c , but well done on astute buying & timing IMHO.
I believe the next 18 months will be transformation for CardieX.

If I look to the end of 2024 :

- ATCOR business in profit, with $25M - $30M of clinical trial annualised sales driven by the Conneqt Pulse device being used in decentralised clinical trials.
- Conneqt Pulse successfully launched into GP/Clinical business in the US, Europe, A/NZ, with sales of 25,000 + Units per quarter ( $5M sales )
- Conneqt Pulse resubmitted to FDA for OTC sales, & granted in mid-2024 / announcement of a couple of large retail contracts ( such as Walgreens )
- Conneqt Band launched at CES2024, FDA submitted Q4,2023 and granted mid 2024. Product launched Aug 2024
- US Listing completed Q3 2023.
- Craig's salary increased to $2M per year in 2024 ( just kidding )

Big Macro Economics ... your guess is as good as mine ... but if CDX can deliver on the above your .25c entry point will be looking brilliant.

IMO